Buy generic Acomplia

Generic Acomplia: Weight Loss PLUS Smoking Cessation

Rimonabant (also known as Zimulti, Acomplia, Slimona or Obitone) is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Rimonabant has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy urges, such as smoking. This is a non-control weightloss solution that in one study, helped people who were overweight drop an average of 20 pounds, and was found to be very useful for patients who suffer from obesity.

How does generic acomplia work?

• Rimonabant acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1
• Rimonabant switches off the same brain circuits that make people hungry when they smoke cannabis
• CB1 receptor blockade with Rimonabant acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.

What Doctors Say About Generic Acomplia

Here are some of the things being said about Acomplia by doctors.

“If there was a pill available that was safe, effective and made it easy to lose any weight at all, there would be a truly massive market.” Dr. Steve Bloom, researcher at Imperial College in London, quoted on June 28, 2006 by Bloomberg

“Acomplia’s been given to 13,000 people but you just don’t completely know what happens when you give it to a million.” Dr. Louis J. Aronne, New York Hospital - Cornell Medical Center, quoted on June 28, 2006 by Bloomberg

“Rimonabant shows a substantial weight reduction, and if that’s possible without side effects it could be promising. I have concerns about the idea you just buy a medocation and that’s it, buying weight reduction instead of changing lifestyle habits.” Dr.Otto Smiseth, a professor of medicine at University of Oslo, quoted on Aug. 29. 2004 by Bloomberg.

“We come up with new medocations on the drawing board all the time, but rarely do they work the way we think they will. This one did. I think the medocation has incredible potential.” Dr. Elbert Glover of West Virginia University Medical School quoted in the Aug. 14, 2004 issue of Newsweek.

If you are not decided to buy Generic acomplia  go to the main pharmacy and ask for more information.There is always online support to help you .

• Acomplia benefits more of the obese people, still it’s useful for smoking community also.
  

• Its trial has confirmed that it is an effective way to relinquish smoking. Although it is one of the most effective weight loss pill.

Acomplia rimonanbant is an appetite suppressant, meaning that when you take it, you will feel less hungry. There are chemicals that tell your brain when you are hungry, and Acomplia rimonanbant works by blocking those messages before they reach your brain. So in effect, you don’t know that you are hungry, and you won’t eat as much! Another interesting effect of Acomplia rimonanbant is that it helps the liver burn fat. It may also help smokers and alcoholics to control cravings for cigarettes and alcohol. In general, Acomplia rimonanbant has the potential to help heal obesity and addiction in new ways.

The primary action of Acomplia ( Rimonanbant ) is to block something called CB-1 receptors. These are areas on the surface of cells that receive chemical messages. When they are blocked, messages that cause people to overeat are stopped. An overweight person who takes Acomplia rimonanbant will not eat as much because he or she will feel fuller faster. As a result, it will be much easier for the person to lose weight and regain the shape he or she lost by overeating in the past.

 The benefits of the new diet pill acomplia

If you suffer from obesity, Acomplia weight loss drug can help you, along with exercise and a low-calorie diet, get your life back. It works by selectively blocking certain receptors in your brain and in turn suppressess your appetite, therefore resulting in safe and effective weight loss. Despite being a drug marketed for obese people, Acomplia’s usefulness for heavy smokers cannot be left unnoticed. Clinical trials have shown that heavy smokers, after being on a regular supplement of Acomplia, have quit smoking altogether. Smokers usually do not stop for fear of weight-gain, which can be highly discouraging. However since Acomplia works on the overeating and smoking factors simultaneously such problems wouldn’t arise. The recommended dosage for Acomplia is one 20mg tablet daily to be taken in the morning before breakfast. It should be swallowed whole with a glass of water, and should not be chewed or crushed as it might contemplate side effects. Research has also shown that Acomplia may help reduce cardiovascular risk factors. It has also been shown to have a beneficial effect on blood glucose and fat levels. More specifically it raises HDL cholesterol levels (the good cholesterol).

We can also include in the benefits of acomplia that Acomplia also appears to help people with type 2 diabetes lose pounds, reduce waist size, and even control blood sugar and blood fats.

Obesity and tobacco abuse, widely recognised as serious health hazards, are increasing in prevalence. Obesity is associated with numerous metabolic complications such as dyslipidemia, type 2 diabetes and cardiovascular diseases. Smoking is a high risk factor for hypertension, lung carcinoma and various other health related problems. The agents that have been used for the treatment of obesity include dexfenfluramine, phentermine, sibutramine and orlistat. Currently, the options for smoking cessation are nicotine patches, gum, lozenges and bupropion. As many of these drugs have serious adverse effects or are unsuitable for maintenance therapy, the search for a novel drug continues.

Rimonabant appears to be a promising drug in an entirely new class called selective cannabinoid (CB1) receptor antagonists. Recent studies have demonstrated the beneficial effects of rimonabant in tackling obesity, smoking cessation and metabolic syndrome. The drug may be approved for treatment of obesity and smoking cessation. Ongoing studies may provide information on its other clinical uses.

Rimonabant has demonstrated a long duration of action (8 hours) and good oral bioavailability.Read more about rimonabant

Buy Rimonabant (Acomplia/Zimulti) Online

        Rimonabant (Acomplia), discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being sold under the trade name Acomplia and under the name as Zimulti in USA.

Acomplia Rimonabant has been approved as a new weight loss drug in a lot of European countries. It is available in many European countries and can be bought online by the consumers from US.

        Acomplia (Rimonabant) is  an oral prescription medication to treat obesity. It woks on the principle of blocking the CB-1 receptors situated in the Endo-cannabinoid system. Consumption of Acomplia primarily blocks the functioning of these receptors, resulting in a decrease of your normal appetite. A reduced appetite means that you would eat less, and in turn loose weight.

Combining a proper diet and workout plan along with Acomplia (Rimonabant) can fetch you optimistic weight loss results. 20mg Acomplia diet pill is the customary dosage which is recommended by doctors for usage. A before-hand consultation with your doctor is required before you commence upon Acomplia (Rimonabant) medication. Never overindulge in usage of Acomplia, as it may be detrimental to your health. Stick your doctors’ advice.

Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use Program involved more than 6,000 subjects. The programme is designed to explore two smoking-related therapies.

How much weight can I lose by taking Acomplia?

        Exhaustive clinical trials conducted with Acomplia on more than 6800 patients yielded substantial results. Patients given Acomplia for a period of one year achieved an average weight loss of six and half kg as compared to just over one and half kg achieved by those on placebo. Most of the weight loss was achieved in the first 9 months of the trial with Acomplia.

Acomplia was also found to reduce the risk of regaining weight. When a group of patients from one of the clinical trials was re-randomized and split into Acomplia and placebo groups, those patients who continued on Acomplia achieved a total weight loss of 7.5 kg over the two year trial period. On the other hand patients who were transferred to placebo achieved a much lower weight loss of only 3.1 kg over the same period.

The best part about Acomplia is that it brings about sizeable reduction in the waist circumference – nearly 6 to 7 cm on an average. This measure is an indication of intra-abdominal fat and is believed to be more important that BMI. If you have a large waist circumference, you should buy Acomplia for reducing it.

 Rimonabant acomplia diet weight loss pills are approved now and will be available on sale in all of 25 European  Union Countries in July.

The European Commission gave permission for the sale of Rimonabant acomplia prescription weight loss drugs  to treat obesity and weight loss  with a BMI ( body mass index) of 30 or above as well as for smoking cessation  treatments.

“The approval of Rimonabant Acomplia in the European Union is important news for obese and overweight  patients with additional cardiometabolic risk factors such as type 2 diabetes or dyslipidaemia who will now have  access to an innovative treatment option,” said Sanofi CEO Jean-François Dehecq.

When you buy Acomplia, tell your doctor about

• History of moderate renal impairment
• Aged over 75 years
• History of epilepsy
• Using potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, nefazodone)
• Hereditary problems of galactose intolerance

Do not take Acomplia if you have

• History of severe renal impairment
• History of uncontrolled serious psychiatric illness such as a major depression.
• History of cardiovascular event (myocardial infarction, stroke, etc.) less than 6 months ago
• Breastfeeding
• Pregnant
• Previously had or currently have depressive illness or suicidal feelings
• Taking antidepressants or any treatment for major depressive illness
• Uncontrolled psychiatric illness (except depression)

Side effects

The possible side effects are listed below:

The possible side effects are listed below:

• General side effects
  • Infections (Upper respiratory tract infection, Gastroenteritis)
  • Mood alterations
  • Memory loss
  • Dizziness
  • Nausea, diarrhea, vomiting
  • Hot flush
  • Skin disorders (pruritus, hyper)
  • Tendonitis, muscle cramps or spasms
  • Asthenia/fatigue influenza
• Rare side effects
  • Panic symptoms, anger, emotional disorder
  • Depressive disorder
  • Suicidal feelings
  • Lethargy
  • Hiccups
  • Night sweats

Acomplia (Rimonabant) is is an oral prescription medication to treat obesity. It woks on the principle of blocking the CB-1 receptors situated in the Endo-cannabinoid system. Consumption of Acomplia primarily blocks the functioning of these receptors, resulting in a decrease of your normal appetite. A reduced appetite means that you would eat less, and in turn loose weight.

Combining a proper diet and workout plan along with Acomplia (Rimonabant) can fetch you optimistic weight loss results. 20mg Acomplia diet pill is the customary dosage which is recommended by doctors for usage. A before-hand consultation with your doctor is required before you commence upon Acomplia (Rimonabant) medication. Never overindulge in usage of Acomplia, as it may be detrimental to your health. Stick your doctors’ advice.

Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use Program involved more than 6,000 subjects. The programme is designed to explore two smoking-related therapies.

Acomplia compared to other weight-loss drugs?

The side-effects of weight-loss-drugs already on the market are quite significant. Xenial for example can in many cases give severe diarrhea making it impossible for some patients to continue using the drug. Meridia (Reductil in Europe) was originally a drug meant to treat depressions and can have severe side-effects as well, like high blood pressure, sleeping problems (Insomnia), constipation and dry-mouth syndrome. Phentermine stimulates the central nervous system, making the body run on “full throttle” all the time. This causes a lot of strain on many of the body systems and phentermine should therefore not be used for longer periods and only in obesity cases and not for treating common overweight.

Buy Acomplia to Show Gateway to Obesity

Are heavy bulges on your body make you look down? Are you tired of vigorous exercise and diet plans? Now no need to fret more! Come out of hibernation and start looking at credible options around. Acomplia diet pills are one such breakthrough and optimal means to fight obesity with advanced arms.

You can also reign above all and can make a cut above the rest with honed body. The only thing you need to acquire is acomplia diet pills. Duly approved by the FDA, Acomplia diet pills are anorectic anti-obesity drug which gently reduce appetite by blocking up CB1 receptors. And EUPharma.co.uk is your one-stop destination where you can buy acomplia at a comparative and attractive price with superlative quality. Outlined to meet all online prescription demands, we, at EUPharma.co.uk proffer a glut of preparations to make all customers replete.

Offering premium quality medicines at lower retail and shipping cost, we take pride in introducing ourselves as an idyllic podium to buy acomplia online. With our immaculate healthcare service, you can buy myriad of medicinal preparations other than just acomplia to savor healthy lifestyle.

We, at EUPharma care for you and your health and thus meticulously monitor your minute to minute demands with precision. So to witness your colossal body being transformed into a slender shape, browse through our fair price table for acomplia.

What is Acomplia ?
Acomplia is now easy to buy online as a prescription drug. Since approval by the European Union for marketing Acomplia as a weight loss drug, millions of people across Europe wish to buy Acomplia. A range of possibilities exist with Rimonabant since it can be used as a treatment for weight loss and effective weight loss management. Acomplia is manufactured by Sanofi-Aventis as an aid to obese people worldwide. Acomplia is now available for US customers with a prescription. All US/North American customers can purchase/buy Acomplia Rimonabant online from Speedyhealth.com for obesity treatment.

How does Acomplia Work?
A certain kind of receptor is blocked by Acomplia (Rimonabant) thus stopping the trigger that governs food intake. The receptors are in the brain, but also throughout the body, most notably in fat cells.
Natural endocannabinoids are blocked by Acomplia and are stopped from attaching to the brain cells which they usually stimulate. This helps prevent the desire to eat and, thus, helps manage weight loss. This is why Acomplia is also known as miracle drug to treat obesity.

Acomplia Rimonabant Clinical Trials
Scores of clinical trials conducted with Acomplia throughout the world in the last two years have shown promising results. It acts on the body in a novel way suppressing cravings, thus reducing food intake for people buying Acomplia.

Clinical data on Acomplia has shown that nearly of the one third of patients treated with 20 milligrams of Acomplia over the full two years lost an excess of 10 per cent of their initial body weight. More than 62 per cent of 20 mg Acomplia patients shed at least 5 per cent of body weight. Waist circumference at two years was reduced by 3.1 inches (8 cm) in the 20 mg Acomplia group, by 1.9 inches (4.9 cm) in a 5 mg Acomplia group, and by just 1.5 inches (3.8 cm) in the placebo group. Across all measures, Acomplia 20mg was more effective than the lower dose and significantly better than placebo.

Overall benefits of Acomplia Rimonabant included an increase in HDL levels by 24.5 per cent and triglyceride reduction by 10 per cent � twice what would be expected from the degree of weight loss as per the research conducted.

Acomplia Rimonabant Side Effects
Side effects in the trial on Acomplia in obesity were vomiting and nausea. Acomplia clinical trials have revealed certain depressive disorders (10% patients), suicidal feelings (1% of patients) and mood changes.

Precautions
Treatment of ongoing major depressive illness and antidepressants are contraindicated with Acomplia. Acomplia rimonabant should not be taken by patients who have or previously had suicidal thoughts or depressive disorder. Acomplia is also not recommended in patients with uncontrolled psychiatric illness exclusive of depression.

Don�t take Acomplia before considering the risk of taking Acomplia yourself and discussing it with your caretakers or relatives. If at anytime you experience any symptoms of depression, stop taking Acomplia rimonabant immediately and seek medical attention.

NEW YORK - An HSBC analyst upgraded Sanofi-Aventis SA Wednesday,Rimonabant brand citing the French drug maker’s full pipeline and shrugging off its failure to receive U.S. approval for the weight-loss drug Acomplia.In late June, Sanofi-Aventis (nyse: SNY - news - people ) withdrew its application to gain U.S. approval for Acomplia, following a meeting in which government advisers rejected the treatment on safety grounds. The Paris-based company said it would resubmit its Food and Drug Administration application for Acomplia at a later date.Despite the Acomplia issues, HSBC (nyse: HBC - news - people ) analyst Kevin Scotcher on Wednesday raised his rating on Sanofi shares to “Overweight” or “Buy” from “Neutral,” citing the company’s new drug portfolio.”Given the share price decline post the failure to commercialise Acomplia in the U.S. in 2007, we nonetheless point out that Sanofi has numerically the fullest pipeline among the 11 U.S. and European drug majors under our coverage,” Scotcher wrote in a note to investors.

HSBC did lower its price target on the shares to 71 euros ($98) from 72.50 euros, however. The analyst pointed to risks including the possibility that Sanofi could launch a highly leveraged takeover of American rival Bristol-Myers Squibb Co. (nyse: BMY - news - people )

Aug. 1 (Bloomberg) — Sanofi-Aventis SA, Europe’s second- biggest drugmaker, reported profit that missed analysts’ estimates on reduced sales of its Ambien sleeping pill and announced a 3 billion-euro ($4.1 billion) share buyback.

Profit excluding takeover costs and writedowns declined 6.1 percent to 1.68 billion euros, or 1.24 euros a share, in the second quarter, down from 1.79 billion euros, or 1.33 euros, a year earlier, the Paris-based company said today. Sanofi was expected to earn 1.79 billion euros in a Bloomberg survey. The shares fell to their lowest level in more than two years.

Generic competition and a dearth of new products Rimonabant brand name caused profit to drop for a fourth quarter. Ambien sales fell 42 percent. Sanofi, which counted on the weight-loss drug Acomplia to boost growth, had to withdraw the U.S. application for the medicine last month after an expert panel linked it to suicide and depression.

“It’s not a good day for Sanofi,” said Paul Diggle, an analyst at Nomura Code Securities in London. “Share buyback or no share buyback, Sanofi is the least of the five European majors I’d be interested in having.”

Sales fell 2 percent to 6.94 billion euros last quarter, while operating profit declined 5 percent to 2.33 billion euros. Consolidated net income was 1.13 billion euros, the company said. The share repurchase will be done before mid-May, Sanofi said.

Sanofi’s stock dropped 2.06 euros,rimonabant availability or 3.4 percent, to 59.44 euros in Paris. Shares of the French drugmaker have fallen 12 percent since a Food and Drug Administration panel rejected Acomplia on June 13. Sanofi plans to provide an update on drug development projects on Sept. 17 in Paris.Unless they can convince people about their pipeline at the R&D day in September, it will be difficult to get people excited, Diggle said.

`Difficult Year’Sanofi repeated its full-year outlook, saying adjusted earnings per share will probably grow 9 percent. The forecast is based on a euro-dollar exchange rate of $1.25. Based on the average euro-dollar exchange rate for the first half of the year of $1.33, Sanofi’s goal would translate into a 4.3 percent gain.

Tags:Rimonabant brand,Rimonabant brand name,rimonabant availability